BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 19926549)

  • 41. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study.
    Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ
    J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.
    Endoh H; Yatabe Y; Shimizu S; Tajima K; Kuwano H; Takahashi T; Mitsudomi T
    Int J Cancer; 2003 Aug; 106(1):45-51. PubMed ID: 12794755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer.
    Li J; Zhang Z; Dai Z; Popkie AP; Plass C; Morrison C; Wang Y; You M
    Neoplasia; 2003; 5(4):362-6. PubMed ID: 14511407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer.
    Sugita H; Iida S; Inokuchi M; Kato K; Ishiguro M; Ishikawa T; Takagi Y; Enjoji M; Yamada H; Uetake H; Kojima K; Sugihara K
    Oncol Rep; 2011 Feb; 25(2):513-8. PubMed ID: 21152877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Takahashi N; Shimazaki Y; Motoyama T
    Cancer Sci; 2003 Jul; 94(7):589-92. PubMed ID: 12841866
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.
    Katayama H; Hiraki A; Fujiwara K; Matsuo K; Maeda T; Chikamori K; Kishino D; Tajima K; Ueoka H; Aoe K
    Asian Pac J Cancer Prev; 2007; 8(2):221-4. PubMed ID: 17696735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance.
    Lee SM; Lee WK; Kim DS; Park JY
    Mol Med Rep; 2012 Jan; 5(1):239-44. PubMed ID: 21971684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer.
    Kim DH; Nelson HH; Wiencke JK; Christiani DC; Wain JC; Mark EJ; Kelsey KT
    Oncogene; 2001 Mar; 20(14):1765-70. PubMed ID: 11313923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Hypermethylation of promoter region of RAS association domain family gene1A in esophageal squamous cell carcinoma and significance thereof].
    Cong DG; Wang SF
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2932-4. PubMed ID: 18261310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
    Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
    Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value.
    Vallböhmer D; Brabender J; Yang D; Schneider PM; Metzger R; Danenberg KD; Hölscher AH; Danenberg PV
    Clin Lung Cancer; 2006 Jul; 8(1):39-44. PubMed ID: 16870044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa.
    Paluszczak J; Misiak P; Wierzbicka M; Woźniak A; Baer-Dubowska W
    Oral Oncol; 2011 Feb; 47(2):104-7. PubMed ID: 21147548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
    Burbee DG; Forgacs E; Zöchbauer-Müller S; Shivakumar L; Fong K; Gao B; Randle D; Kondo M; Virmani A; Bader S; Sekido Y; Latif F; Milchgrub S; Toyooka S; Gazdar AF; Lerman MI; Zabarovsky E; White M; Minna JD
    J Natl Cancer Inst; 2001 May; 93(9):691-9. PubMed ID: 11333291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
    Kim DH; Kim JS; Park JH; Lee SK; Ji YI; Kwon YM; Shim YM; Han J; Park J
    Cancer Res; 2003 Oct; 63(19):6206-11. PubMed ID: 14559805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
    Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
    Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
    Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
    Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer.
    Tang LP; Cho CH; Hui WM; Huang C; Chu KM; Xia HH; Lam SK; Rashid A; Wong BC; Chan AO
    Digestion; 2006; 74(2):85-90. PubMed ID: 17139167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression.
    Iliopoulos D; Oikonomou P; Messinis I; Tsezou A
    Oncol Rep; 2009 Jul; 22(1):199-204. PubMed ID: 19513524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.
    Hoffmann AC; Kaifi JT; Vallböhmer D; Yekebas E; Grimminger P; Leers JM; Izbicki JR; Hölscher AH; Schneider PM; Metzger R; Brabender J
    J Surg Oncol; 2009 Oct; 100(5):414-7. PubMed ID: 19653236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.